[go: up one dir, main page]

ECSP088241A - AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME - Google Patents

AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME

Info

Publication number
ECSP088241A
ECSP088241A EC2008008241A ECSP088241A ECSP088241A EC SP088241 A ECSP088241 A EC SP088241A EC 2008008241 A EC2008008241 A EC 2008008241A EC SP088241 A ECSP088241 A EC SP088241A EC SP088241 A ECSP088241 A EC SP088241A
Authority
EC
Ecuador
Prior art keywords
methods
cytotoxic
antigen
specific
same
Prior art date
Application number
EC2008008241A
Other languages
Spanish (es)
Inventor
Daniel Tavares
Gillian Payne
Philip Chun
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of ECSP088241A publication Critical patent/ECSP088241A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen conjugados citotóxicos que comprenden un agente de enlace celular y un agente citotóxico, composiciones terapéuticas que comprenden el conjugado, métodos para usar los conjugados en la inhibición del crecimiento celular y el tratamiento de la enfermedad, y un equipo que comprende el conjugado citotóxico en todas las modalidades de la invención. En particular, el agente de enlace celular es un anticuerpo monoclonal, y fragmentos de enlace de epítope del mismo, que reconoce y enlaza el glicótopo CA6. La presente invención también está dirigida a versiones humanizadas o recubiertas de DS6, un anticuerpo monoclonal anti-CA6 murino, y fragmentos de enlace de epítope del mismo.Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and treatment of the disease, and a kit comprising the cytotoxic conjugate are described in all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope binding fragments thereof, which recognizes and binds the CA6 glycopepo. The present invention is also directed to humanized or coated versions of DS6, a murine anti-CA6 monoclonal antibody, and epitope binding fragments thereof.

EC2008008241A 2005-08-22 2008-03-05 AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME ECSP088241A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/030115 WO2007024222A1 (en) 2005-08-22 2005-08-22 A ca6 antigen-specific cytotoxic conjugate and methods of using the same

Publications (1)

Publication Number Publication Date
ECSP088241A true ECSP088241A (en) 2008-04-28

Family

ID=37771883

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008241A ECSP088241A (en) 2005-08-22 2008-03-05 AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME

Country Status (13)

Country Link
EP (1) EP1917034A4 (en)
JP (1) JP2009504193A (en)
CN (1) CN101242855A (en)
AU (1) AU2005335743A1 (en)
BR (1) BRPI0520509A2 (en)
CA (1) CA2615761A1 (en)
EA (1) EA020130B9 (en)
EC (1) ECSP088241A (en)
HK (1) HK1211965A1 (en)
IL (2) IL189628A0 (en)
MX (1) MX2008002607A (en)
NO (1) NO20080893L (en)
WO (1) WO2007024222A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
US9989524B2 (en) 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
SI2953975T1 (en) * 2013-02-05 2018-02-28 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US9844607B2 (en) 2013-02-05 2017-12-19 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
HUE037909T2 (en) * 2013-02-05 2018-09-28 Sanofi Sa Immuno imaging agent for use with antibody-drug conjugate therapy
JP2016525560A (en) * 2013-08-02 2016-08-25 サノフイ Use of anti-Muc1 maytansinoid immunoconjugate antibodies to treat solid tumors
US20160058884A1 (en) 2014-09-02 2016-03-03 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
TW202417447A (en) 2014-09-03 2024-05-01 美商免疫原公司 Cytotoxic benzodiazepine derivatives
TW201613930A (en) 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
FI3380525T3 (en) 2015-11-25 2024-01-30 Immunogen Inc Pharmaceutical formulations and methods of use thereof
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
IL298414B2 (en) 2017-02-28 2024-12-01 Immunogen Inc History of ethansinoids with peptide linkers and their conjugates
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596503B1 (en) * 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
CN1816356A (en) * 2003-05-14 2006-08-09 免疫原公司 drug conjugate composition
EP1660513B9 (en) * 2003-07-21 2012-04-04 ImmunoGen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same

Also Published As

Publication number Publication date
BRPI0520509A2 (en) 2009-05-12
EA200800642A1 (en) 2008-08-29
EP1917034A1 (en) 2008-05-07
MX2008002607A (en) 2008-03-19
IL189628A0 (en) 2008-06-05
WO2007024222A1 (en) 2007-03-01
EP1917034A4 (en) 2009-04-29
IL238798A0 (en) 2015-06-30
EA020130B1 (en) 2014-08-29
EA020130B9 (en) 2014-10-30
CN101242855A (en) 2008-08-13
JP2009504193A (en) 2009-02-05
NO20080893L (en) 2008-05-22
HK1211965A1 (en) 2016-06-03
CA2615761A1 (en) 2007-03-01
AU2005335743A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
ECSP088241A (en) AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME
ECSP066294A (en) AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME
MX2007011064A (en) Antibodies against cd38 for treatment of multiple myeloma.
EA201100923A1 (en) HUMAN ANTIBODIES AGAINST THE TISSUE FACTOR
CR10308A (en) HUMANIZED MONOCLONAL ANTIBODIES FOR THE HEPATOCITE GROWTH FACTOR
CY1112277T1 (en) HUMANIZED ANTI-β7 COMPETITORS AND THEIR USES
CL2008003361A1 (en) Monoclonal antibodies that bind to hgm-csf and the average compositions that comprise them.
AR057807A1 (en) ANTI-CD3 ANTIBODY FORMULATIONS
SG153825A1 (en) Multivalent immunoglobulin-based bioactive assemblies
EA200800952A1 (en) CONJUGATES ANTIBODY-DRUG AND METHODS OF APPLICATION
EA201270625A1 (en) LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY
EA200970923A1 (en) ANTI-EpSAM ANTIBODY AND ITS APPLICATION
AR051925A1 (en) ANTI-OX4OL ANTIBODIES
CY1111622T1 (en) ANTI-CMET HUMANIZED COMPETITORS
EA200700083A1 (en) ANTIBODIES DIRECTED AGAINST BETA AMYLOID PEPTIDE, AND METHODS OF THEIR APPLICATION
NO20076404L (en) Humanized anti-CD40 antibodies and their methods of use
DK2109623T3 (en) Cancer treatment with anti-IL-1 antibodies
EA202193309A1 (en) ANTIBODY TO TISSUE FACTOR-DRUG CONJUGATES AND RELATED METHODS
CR9823A (en) AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
MX2023001625A (en) IMMUNOCONJUGATES THAT TARGET CD46 AND METHODS OF USE THEREOF.
CR20140095A (en) AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME
EA202190387A1 (en) ANTIBODY TO HUMAN CD38 AND ITS USE